Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Inglés |
| Publicado: |
Frontiers Media
2021
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/11620 |
| Aporte de: |
| id |
I33-R139123456789-11620 |
|---|---|
| record_format |
dspace |
| institution |
Universidad Católica Argentina |
| institution_str |
I-33 |
| repository_str |
R-139 |
| collection |
Repositorio Institucional de la Universidad Católica Argentina (UCA) |
| language |
Inglés |
| topic |
MELATONINA ENFERMEDAD DE PARKINSON ENVEJECIMIENTO NEURODEGENERACION ENFERMEDADES NEURODEGENERATIVAS TRATAMIENTO MEDICO |
| spellingShingle |
MELATONINA ENFERMEDAD DE PARKINSON ENVEJECIMIENTO NEURODEGENERACION ENFERMEDADES NEURODEGENERATIVAS TRATAMIENTO MEDICO Pérez Lloret, Santiago Cardinali, Daniel Pedro Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
| topic_facet |
MELATONINA ENFERMEDAD DE PARKINSON ENVEJECIMIENTO NEURODEGENERACION ENFERMEDADES NEURODEGENERATIVAS TRATAMIENTO MEDICO |
| description |
Abstract: This article discusses the role that melatonin may have in the prevention and treatment of
Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are
consistently disrupted and the potential therapeutic value of melatonin on sleep
disorders in PD was examined in a limited number of clinical studies using 2–5mg/
day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in
substantia nigra and amygdala found in PD patients supported the hypothesis that the
altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system.
Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells
in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like
rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may
precede the onset of motor symptoms in PD for years and are index of worse prognosis.
Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset.
Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in
RDB treatment and may halt neurodegeneration to PD. In studies on animal models of
PD melatonin was effective to curtail symptomatology in doses that allometrically
projected to humans were in the 40–100 mg/day range, rarely employed clinically.
Therefore, double-blind, placebo-controlled clinical studies are urgently needed in
this respect. |
| format |
Artículo |
| author |
Pérez Lloret, Santiago Cardinali, Daniel Pedro |
| author_facet |
Pérez Lloret, Santiago Cardinali, Daniel Pedro |
| author_sort |
Pérez Lloret, Santiago |
| title |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
| title_short |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
| title_full |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
| title_fullStr |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
| title_full_unstemmed |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
| title_sort |
melatonin as a chronobiotic and cytoprotective agent in parkinson’s disease |
| publisher |
Frontiers Media |
| publishDate |
2021 |
| url |
https://repositorio.uca.edu.ar/handle/123456789/11620 |
| work_keys_str_mv |
AT perezlloretsantiago melatoninasachronobioticandcytoprotectiveagentinparkinsonsdisease AT cardinalidanielpedro melatoninasachronobioticandcytoprotectiveagentinparkinsonsdisease |
| bdutipo_str |
Repositorios |
| _version_ |
1764820525117341698 |